Mason Ryan H, Minaker Samuel A, Lahaie Luna Gabriela, Bapat Priya, Farahvash Armin, Garg Anubhav, Bhambra Nishaant, Muni Rajeev H
Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, ON, Canada.
Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, ON, Canada.
Eye (Lond). 2022 Jun 7. doi: 10.1038/s41433-022-02127-x.
Diabetic retinopathy is a major complication of diabetes mellitus, where in its most advanced form ischemic changes lead to the development of retinal neovascularization, termed proliferative diabetic retinopathy (PDR). While the development of PDR is often associated with angiogenic and inflammatory cytokines, studies differ on which cytokines are implicated in disease pathogenesis and on the strength of these associations. We therefore conducted a systematic review and meta-analysis to quantitatively assess the existing body of data on intraocular cytokines as biomarkers in PDR.
A comprehensive search of the literature without year limitation was conducted to January 18, 2021, which identified 341 studies assessing vitreous or aqueous cytokine levels in PDR, accounting for 10379 eyes with PDR and 6269 eyes from healthy controls. Effect sizes were calculated as standardized mean differences (SMD) of cytokine concentrations between PDR and control patients.
Concentrations (SMD, 95% confidence interval, and p-value) of aqueous IL-1β, IL-6, IL-8, MCP-1, TNF-α, and VEGF, and vitreous IL-2, IL-4, IL-6, IL-8, angiopoietin-2, eotaxin, erythropoietin, GM-CSF, GRO, HMGB-1, IFN-γ, IGF, IP-10, MCP-1, MIP-1, MMP-9, PDGF-AA, PlGF, sCD40L, SDF-1, sICAM-1, sVEGFR, TIMP, TNF-α, and VEGF were significantly higher in patients with PDR when compared to healthy nondiabetic controls. For all other cytokines no differences, failed sensitivity analyses or insufficient data were found.
This extensive list of cytokines speaks to the complexity of PDR pathogenesis, and informs future investigations into disease pathogenesis, prognosis, and management.
糖尿病视网膜病变是糖尿病的一种主要并发症,在其最严重的形式中,缺血性改变会导致视网膜新生血管形成,即增殖性糖尿病视网膜病变(PDR)。虽然PDR的发生通常与血管生成和炎性细胞因子有关,但关于哪些细胞因子参与疾病发病机制以及这些关联的强度,研究结果存在差异。因此,我们进行了一项系统综述和荟萃分析,以定量评估关于眼内细胞因子作为PDR生物标志物的现有数据。
对截至2021年1月18日的无年份限制的文献进行全面检索,共识别出341项评估PDR患者玻璃体或房水中细胞因子水平的研究,涉及10379只患PDR的眼睛和6269只来自健康对照者的眼睛。效应大小以PDR患者与对照患者之间细胞因子浓度的标准化平均差异(SMD)计算。
与健康非糖尿病对照者相比,PDR患者房水中白细胞介素-1β(IL-1β)、IL-6、IL-8、单核细胞趋化蛋白-1(MCP-1)、肿瘤坏死因子-α(TNF-α)和血管内皮生长因子(VEGF),以及玻璃体中IL-2、IL-4、IL-6、IL-8、血管生成素-2、嗜酸性粒细胞趋化蛋白、促红细胞生成素、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、生长调节致癌基因(GRO)、高迁移率族蛋白B1(HMGB-1)、干扰素-γ(IFN-γ)、胰岛素样生长因子(IGF)、干扰素诱导蛋白10(IP-10)、MCP-1、巨噬细胞炎性蛋白-1(MIP-1)、基质金属蛋白酶-9(MMP-9)、血小板衍生生长因子-AA(PDGF-AA)、胎盘生长因子(PlGF)、可溶性CD40配体(sCD40L)、基质细胞衍生因子-1(SDF-1)、可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管内皮生长因子受体(sVEGFR)、金属蛋白酶组织抑制因子(TIMP)、TNF-α和VEGF的浓度显著更高。对于所有其他细胞因子,未发现差异、敏感性分析失败或数据不足。
这份详尽的细胞因子清单表明了PDR发病机制的复杂性,并为未来对疾病发病机制、预后和管理的研究提供了信息。